查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863118

正子放出斷層攝影(PET)- 市場趨勢，競爭情形，市場預測(2032年)

Positron Emission Tomography - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

正子放出斷層攝影(PET)的摘要

  • 全球正子斷層掃描 (PET) 市場預計將從 2024 年的 19.3385 億美元成長到 2032 年的 31.274 億美元，呈現強勁且持續的成長態勢。
  • 全球正子斷層掃描 (PET) 市場預計在 2025 年至 2032 年間以 6.23% 的複合年增長率 (CAGR) 成長。
  • 推動市場成長的主要因素包括心血管疾病和神經系統疾病（例如阿茲海默症）等慢性疾病盛行率的上升，以及全球技術的快速發展。
  • PET市場的主要企業包括通用電氣公司、布魯克公司、西門子醫療有限公司、皇家飛利浦公司、佳能醫療系統株式會社、Positron公司、島津公司、RefleXion公司、CMR Naviscan公司、Segami公司、東軟醫療系統醫療系統有限公司、MedisoMR公司、Sofie Biosciences Solutions（Perkinin）公司（Foundin BioMin）公司式公司。
  • 預計北美將引領整個PET市場。該地區市場成長的主要驅動力是癌症等慢性疾病和帕金森氏症等神經退化性疾病發生率的上升。
  • 在PET類型細分市場中，預計全環PET掃描器將在2024年佔據最大的市場佔有率。

正子斷層掃描（PET）市場成長驅動因素

  • 慢性疾病的增加：慢性疾病發生率的不斷上升是推動PET影像技術普及的主要因素。癌症、心血管疾病和神經系統疾病（包括阿茲海默症）等疾病需要準確及時的診斷工具才能有效管理。 PET在分子層面上檢測功能異常具有很高的靈敏度，因此對於疾病分期、追蹤和治療計劃至關重要。例如，隨著全球人口老化，神經退化性疾病和腫瘤的盛行率持續上升，顯著擴大了依賴PET影像進行及時診斷和治療的患者群體。
  • 正子斷層掃描 (PET) 技術進步推動市場成長：PET 影像技術的持續進步和創新顯著提高了診斷準確性並拓展了應用範圍。混合 PET/CT 和 PET/MRI 系統、高靈敏度全身 PET 掃描儀以及新型放射性追蹤劑的開發，使得疾病的早期檢測和治療效果的全面評估成為可能。例如，全身 PET 技術在腫瘤學、心臟病學和神經病學領域尤其重要，因為它既能縮短掃描時間、減少輻射暴露，又能提供卓越的影像品質。這些進步正在增強 PET 的臨床應用價值，並加速其在全球的普及。
  • 與其他影像方式的整合：PET 與 CT 和 MRI 等互補成像技術的整合，透過在單次掃描中結合功能資訊和解剖結構訊息，顯著提高了診斷能力。 PET 可捕捉代謝和分子層面的活動，而 CT 和 MRI 則提供詳細的結構視覺化，從而實現更精確的疾病檢測、分期和治療計劃。這種多學科方法提高了診斷準確性，支持精準醫療，並正迅速成為先進臨床影像的標準。隨著醫療保健系統不斷優先考慮成本效益和改善患者預後，基於PET的整合影像解決方案的採用率預計將穩定成長。

本報告探討並分析了全球正子斷層掃描（PET）市場，指出了關鍵趨勢、成長驅動因素、挑戰和機會。

目錄

第1章 正子放出斷層攝影(PET)市場報告概要

  • 調查範圍
  • 市場區隔
  • 市場估計

第2章 正子放出斷層攝影(PET)市場摘要整理

  • 市場概要

第3章 正子放出斷層攝影(PET)市場主要原因的分析

  • 正子放出斷層攝影(PET)市場促進因素
  • 正子放出斷層攝影(PET)市場阻礙因素與課題
  • 正子放出斷層攝影(PET)市場機會

第4章 影響的分析

  • 活用了AI的革新與用途
  • 美國關稅的影響的分析

第5章 法規分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章 正子放出斷層攝影(PET)市場波特的五力分析

第7章 正子放出斷層攝影(PET)市場評估

  • 各類型
    • 全環 PET 掃描儀
    • 部分環 PET 掃描儀
  • 各用途
    • 腫瘤
    • 心臟
    • 其他
  • 各終端用戶
    • 醫院
    • 診斷影像中心
  • 地區
    • 北美
    • 歐洲
    • 亞太地區
    • 其他地區

第8章 競爭情形

第9章 新創企業融資與投資趨勢

第10章 正子放出斷層攝影(PET)市場企業與產品的簡介

  • General Electric Company
  • Bruker Corporation
  • Siemens Healthcare GmbH.
  • Koninklijke Philips N.V.
  • Canon Medical Systems Corporation
  • Positron Corporation
  • Shimadzu Corp.
  • RefleXion
  • CMR Naviscan Corporation
  • Segami Corporation
  • Neusoft Medical Systems Co., Ltd.
  • Mediso Ltd.
  • Sofie Biosciences(PerkinElmer Inc.)
  • United Imaging Healthcare Co., Ltd.
  • MinFound Medical Systems Co., Ltd.
  • MR Solutions

第11章 KOL的見解

第12章 計劃方法

第13章 關於DelveInsight

第14章 免責聲明，諮詢方式

Product Code: DIMDCL0297

Positron Emission Tomography Summary

  • The global positron emission tomography is expected to increase from USD 1,933.85 million in 2024 to USD 3,127.40 million by 2032, reflecting strong and sustained growth.
  • The global positron emission tomography is growing at a CAGR of 6.23% during the forecast period from 2025 to 2032.
  • The market of positron emission tomography solutions is being primarily driven by the rising prevalence of chronic diseases such as cardiovascular and neurological disorders, including Alzheimer's disease, and increasing technological advancements globally.
  • The leading companies operating in the positron emission tomography include General Electric Company, Bruker Corporation, Siemens Healthcare GmbH, Koninklijke Philips N.V., Canon Medical Systems Corporation, Positron Corporation, Shimadzu Corp., RefleXion, CMR Naviscan Corporation, Segami Corporation, Neusoft Medical Systems Co., Ltd., Mediso Ltd., Sofie Biosciences (PerkinElmer Inc.), United Imaging Healthcare Co., Ltd., MinFound Medical Systems Co., Ltd, MR Solutions, and others.
  • North America is anticipated to dominate the overall positron emission tomography market. The region's market growth is primarily driven by increasing instances of chronic diseases such as cancer and neurodegenerative conditions like Parkinson's disease.
  • In the type segment of the positron emission tomography, the Full-Ring PET ccanners category is estimated to account for the largest market share in 2024.

Factors Contributing to the Growth of Positron Emission Tomography

  • Rising Prevalence of Chronic Diseases: The growing cases of chronic diseases are a major factor fueling the adoption of PET imaging. Conditions such as cancer, cardiovascular disorders, and neurological diseases, including Alzheimer's, require accurate and early diagnostic tools for effective management. PET provides high sensitivity in detecting functional abnormalities at the molecular level, making it indispensable in disease staging, monitoring, and treatment planning. For instance, as the global population ages, the prevalence of neurodegenerative and oncological conditions continues to rise, creating a substantial patient pool that relies on PET imaging for timely diagnosis and care.
  • Technological Advancements in Positron Emission Tomography Modalities Fueling Market Growth: Continuous advancements and innovations in PET imaging technologies are significantly improving diagnostic precision and expanding the scope of applications. Developments such as hybrid PET/CT and PET/MRI systems, total-body PET scanners with higher sensitivity, and novel radiotracers are enabling earlier detection of diseases and more comprehensive evaluation of treatment responses. For example, total-body PET technology reduces scan times and radiation exposure while providing superior image quality, making it particularly valuable for oncology, cardiology, and neurology. These advancements are strengthening the clinical utility of PET and accelerating its global adoption.
  • Integration with Other Imaging Modalities: The integration of PET with complementary imaging techniques such as CT and MRI has significantly enhanced diagnostic capabilities by combining functional and anatomical insights in a single scan. While PET captures metabolic and molecular activity, CT and MRI provide detailed structural visualization, resulting in more accurate disease detection, staging, and treatment planning. This multimodal approach improves diagnostic confidence, supports precision medicine, and is increasingly becoming the standard in advanced clinical imaging. As healthcare systems continue to emphasize cost-effectiveness and better patient outcomes, the adoption of integrated PET-based imaging solutions is expected to rise steadily.

Positron Emission Tomography Report Segmentation

This positron emission tomography report offers a comprehensive overview of the global positron emission tomography, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Positron Emission Tomography by Type (Full-Ring PET Scanners, Partial Ring PET Scanners), Application (Oncology, Cardiology, Neurology, and Others), End-User (Hospital, Diagnostic Imaging Centres, and Others), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing positron emission tomography market.

Positron emission tomography (PET) is a non-invasive nuclear imaging technique that provides detailed insights into the body's metabolic and physiological processes. By using radiotracers that emit positrons, PET captures high-resolution images to detect abnormal cellular activity, enabling early diagnosis and monitoring of conditions such as cancer, cardiovascular disease, and neurological disorders. Its ability to reveal functional changes at the molecular level, often before structural abnormalities appear, makes PET a critical tool in precision diagnostics, treatment planning, and personalized medicine.

The growth of the global PET market is primarily driven by the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions, which is creating a strong demand for accurate and early diagnostic solutions. Alongside this, continuous technological advancements, including hybrid imaging systems, novel radiotracers, and total-body PET scanners, are significantly enhancing diagnostic precision and broadening clinical applications. Furthermore, the integration of PET with other imaging modalities such as CT and MRI is improving diagnostic confidence, treatment planning, and overall patient management. Collectively, these factors are positioning PET as a vital tool in modern healthcare, supporting its robust market growth during the forecast period from 2025 to 2032.

What are the latest Positron Emission Tomography Dynamics and Trends?

The increasing global cases of chronic disorders, particularly cancer, cardiovascular diseases, and neurological conditions, are a primary factor for the growth of the PET market. PET imaging has become an indispensable tool in oncology, cardiology, and neurology by enabling highly sensitive detection of metabolic and functional changes at the molecular level, often before structural abnormalities appear. This early diagnostic advantage allows for accurate disease staging, monitoring of treatment response, and more personalized therapeutic strategies, making PET central to the management of some of the world's most prevalent and life-threatening conditions. According to DelveInsight's recent estimates, the number of new cancer cases globally is projected to rise significantly, surpassing 30 million by 2050, primarily due to population growth and aging. This mounting burden is creating a sustained demand for advanced imaging solutions capable of delivering precise, real-time insights into disease progression.

The rising cases of cardiovascular and neurological disorders further underscore the critical role of PET in modern healthcare. In cardiology, PET is increasingly applied to assess myocardial perfusion and viability, helping guide interventions for millions affected by heart disease. In neurology, PET is instrumental in diagnosing and tracking neurodegenerative conditions such as Alzheimer's disease, offering clinicians vital information for patient management as these disorders continue to escalate worldwide. The market is not only responding to this demand but is also being reshaped by technological innovation. A recent example includes Brightonix Imaging's announcement that its flagship product, the PHAROS PET Scanner, received FDA clearance for commercial distribution in the United States. This milestone marks a new era of precision and efficiency in nuclear imaging, positioning Brightonix Imaging at the forefront of medical innovation and setting new standards in diagnostic accuracy.

While Positron Emission Tomography offers unmatched functional and molecular insights, its growth is restrained by the presence of alternative imaging options and stringent regulatory frameworks. Conventional modalities such as CT and MRI are more widely available, less costly, and free from radiation exposure, making them preferred choices in many diagnostic scenarios and limiting PET adoption to complex cases requiring deeper metabolic analysis. Adding to this challenge are the rigorous approval processes for PET scanners and radiopharmaceuticals, which involve extensive safety testing, high compliance costs, and prolonged timelines. These constraints collectively slow down innovation, increase market entry barriers, and restrict wider accessibility of PET technologies despite their proven clinical value.

Positron Emission Tomography Segment Analysis

Positron Emission Tomography by Type (Full-Ring PET Scanners and Partial Ring PET Scanners), Application (Oncology, Cardiology, Neurology, and Others), End-User (Hospital, Diagnostic Imaging Centres, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

By Type: Full-Ring PET Scanners Category Dominates the Market

Within the type segment of positron emission tomography, Full-Ring PET Scanners are a dominant force, projected to maintain a significant market share of around 65% in 2024. The market for full-ring PET scanners is expanding at an accelerated pace, driven by their unparalleled ability to deliver high-resolution, whole-body imaging with superior sensitivity. These systems utilize a complete 360-degree detector ring, enabling simultaneous acquisition of comprehensive data and reducing image artifacts, which results in sharper images and more reliable diagnostic outcomes. This makes them particularly valuable in oncology for detecting tumors at earlier stages, in cardiology for assessing myocardial perfusion with precision, and in neurology for mapping complex brain disorders such as Alzheimer's disease.

Technological progress has further reinforced this trend, with the integration of silicon photomultipliers (SiPMs) and advanced time-of-flight (TOF) capabilities significantly improving image clarity while cutting down on scan times and radiation doses. Product development is also playing a vital role in shaping adoption: GE Healthcare's Discovery MI Gen 2 has set new benchmarks for clinical accuracy, Siemens Healthineers' Biograph Vision Quadra offers an extended axial field of view for faster and more detailed imaging, and United Imaging's groundbreaking uEXPLORER provides total-body PET imaging, enabling dynamic studies that were previously unattainable. Collectively, these innovations are expanding the clinical utility of full-ring PET scanners beyond conventional oncology into areas like immunotherapy monitoring, pharmacokinetic studies, and population health research, thereby propelling their rapid market growth worldwide.

By Application: Oncology Category Dominates the Market

In the application segment, oncology continues to dominate the positron emission tomography (PET) market, accounting for more than 55% of the market share in 2024, serving as its primary growth factor. The rising global burden of cancers such as lung, liver, kidney, and bone has intensified the demand for precise imaging solutions that enable early detection, accurate staging, and effective treatment monitoring. PET imaging, with its ability to visualize metabolic activity at the cellular level, has become an indispensable tool in oncology, offering clinicians vital insights into tumor behavior and treatment response. Furthermore, the integration of PET with advanced modalities like PET/CT and PET/MRI is enhancing diagnostic accuracy and expanding its clinical utility across a wider range of malignancies. Collectively, these factors firmly position oncology as the leading driver of PET adoption worldwide..

By End-User: Hospitals Category Dominates the Market

The hospital segment dominates the end-user landscape of the positron emission tomography (PET) market, accounting for approximately 60% of the market share in 2024, largely due to its role as a primary hub for advanced diagnostic imaging. Hospitals are equipped with the infrastructure and resources necessary to house full-scale PET systems, which require specialized facilities, radioactive tracer handling, and integration with complementary imaging modalities like CT or MRI. They also benefit from access to multidisciplinary teams of oncologists, neurologists, cardiologists, and radiologists, who rely on PET scans for accurate diagnosis, staging, and treatment monitoring of complex conditions. Moreover, favorable reimbursement policies, high patient inflow, and the rising demand for early cancer and neurological disorder detection further reinforce hospitals as the preferred setting for PET imaging. While diagnostic imaging centers are expanding their presence with cost-effective offerings, hospitals are expected to maintain the largest market share, driven by their comprehensive service capabilities and ability to manage high-acuity cases.

Positron Emission Tomography Regional Analysis

North America Positron Emission Tomography Trends

In 2024, North America is projected to account for the largest share of the global positron emission tomography market, representing approximately 40%, driven by the rising prevalence of chronic diseases such as cancer and neurodegenerative disorders like Parkinson's disease. The region's growth is further supported by its advanced healthcare infrastructure, favorable reimbursement framework, and strong presence of leading imaging technology providers. The U.S. remains the frontrunner, with rapid adoption of innovative PET systems and substantial investments in R&D reinforcing its leadership position.

The United States, in particular, faces a significant and growing number of cancer cases. According to DelveInsight analysis, more than 1.85 million new cancer cases are expected to be diagnosed in the U.S. in 2025, and this number is projected to increase in the coming years due to an aging population and other demographic shifts. Thus, the growing burden of cancer in the United States is significantly fueling the adoption of PET imaging, as it enables accurate diagnosis, staging, and treatment monitoring. With the aging population and shifting demographics further increasing disease prevalence, the demand for advanced PET systems continues to rise.

Beyond oncology, the PET market is also being propelled by the rising cases of neurological disorders. Analysts highlight that nearly one million people in the U.S. are currently living with Parkinson's disease, a figure expected to rise to 1.21 million by 2030. This growing disease burden, combined with North America's advanced healthcare infrastructure, high healthcare expenditure, and strong preference for minimally invasive diagnostic procedures, continues to drive market growth in the region.

Europe Positron Emission Tomography Trends

The Europe positron emission tomography market is witnessing steady growth, supported by the rising incidence of cancer and neurological disorders, coupled with an increasing focus on early and accurate diagnosis. Strong government initiatives to improve cancer screening programs, favorable reimbursement frameworks, and the widespread adoption of advanced imaging technologies are further accelerating adoption. The presence of leading research institutions and collaborations between healthcare providers and imaging companies are fostering innovation, particularly in hybrid PET modalities and radiotracer development. Additionally, growing investments in precision medicine and personalized treatment approaches are enhancing the clinical value of PET, positioning Europe as a vital hub for technological advancement and market expansion.

Asia-Pacific Positron Emission Tomography Trends

The Asia-Pacific positron emission tomography (PET) market is witnessing rapid growth, driven by the rising incidence of cancer, cardiovascular disorders, and neurological conditions across the region. Increasing healthcare expenditure, expanding access to advanced diagnostic imaging, and government initiatives to strengthen cancer screening and early detection programs are further fueling adoption. Countries such as China, Japan, and India are emerging as key markets, supported by a growing patient pool, rising awareness of early disease diagnosis, and the availability of more cost-effective PET technologies. Moreover, collaborations between global manufacturers and local healthcare providers are enhancing access to cutting-edge imaging systems. With continuous investments in healthcare infrastructure and an expanding medical tourism industry, the Asia-Pacific is expected to be one of the fastest-growing regions in the global PET market.

Who are the major players in Positron Emission Tomography?

The following are the leading companies in Positron Emission Tomography. These companies collectively hold the largest market share and dictate industry trends.

  • General Electric Company
  • Bruker Corporation
  • Siemens Healthcare GmbH
  • Koninklijke Philips N.V.
  • Canon Medical Systems Corporation
  • Positron Corporation
  • Shimadzu Corp.
  • RefleXion
  • CMR Naviscan Corporation
  • Segami Corporation
  • Neusoft Medical Systems Co., Ltd.
  • Mediso Ltd.
  • Sofie Biosciences (PerkinElmer Inc.)
  • United Imaging Healthcare Co., Ltd.
  • MinFound Medical Systems Co., Ltd
  • MR Solutions

How is the competitive landscape shaping the Positron emission tomography?

The competitive landscape of the PET market is moderately concentrated, with a few global leaders driving technological innovation and commanding significant market share, while regional players and emerging startups contribute to specialized advancements. Leading companies are investing heavily in R&D to introduce next-generation PET solutions that feature hybrid imaging modalities, improved radiotracers, and AI-powered analysis, pushing the industry toward faster, safer, and more precise diagnostics. Key competitive strategies include continuous product innovation, strategic collaborations with hospitals, research institutions, and pharmaceutical firms, as well as expansion into new clinical applications such as neurology and cardiology. Meanwhile, regional players are gaining traction in emerging markets by offering cost-effective systems and localized radiotracer production. Overall, competition in the PET market is intensifying as both established players and new entrants strive to capture opportunities driven by rising disease prevalence, growing demand for precision diagnostics, and rapid technological progress.

Recent Developmental Activities in Positron Emission Tomography

  • In June 2025, GE HealthCare announced that the U.S. Food and Drug Administration approved an updated label for its PET imaging agent Vizamyl(TM) (flutemetamol F 18 injection) for beta-amyloid detection.
  • In Feb 2025, Telix Pharmaceuticals announced that the FDA accepted the Biologics License Application (BLA) for TLX250-CDx (Zircaix(R)), a breakthrough kidney cancer PET imaging agent. The FDA granted a Priority Review and set a PDUFA date of August 27, 2025, for a potential U.S. launch.

Positron Emission Tomography Segmentation

  • Positron Emission Tomography Type Exposure
  • Full-Ring PET Scanners
  • Partial Ring PET Scanners
  • Positron Emission Tomography Application Exposure
  • Oncology
  • Cardiology
  • Neurology
  • Others
  • Positron Emission Tomography End-Users Exposure
  • Hospitals
  • Diagnostic Imaging Centres
  • Others
  • Positron Emission Tomography Geography Exposure
  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • Rest of the World
  • South America
  • Middle East
  • Africa

Impact Analysis

AI-Powered Innovations and Applications:

Artificial Intelligence (AI) is transforming the PET market by bringing greater precision, efficiency, and clinical value to imaging. AI-driven algorithms enhance image reconstruction, reduce noise, and minimize radiation exposure, resulting in clearer images and safer procedures for patients. These technologies also enable automated quantification and pattern recognition, allowing for earlier and more reliable detection of conditions such as cancer, Alzheimer's disease, and cardiovascular disorders. Beyond diagnostics, AI supports workflow optimization, predictive scheduling, and personalized treatment planning, helping healthcare providers improve efficiency and patient outcomes. Its growing role in clinical trials and drug development further expands the utility of PET imaging, positioning AI-powered PET as a critical enabler of precision medicine and next-generation healthcare delivery.

U.S. Tariff Impact Analysis on Positron Emission Tomography:

Tariffs play a critical role in shaping the cost dynamics of advanced medical imaging technologies such as PET systems. The U.S. healthcare market is highly dependent on imported PET scanners, radiotracers, and key components sourced from global manufacturers. Any increase in import tariffs on medical imaging equipment or electronic components directly raises procurement costs for healthcare providers, thereby impacting overall market growth. Higher tariffs can also affect the supply chain by creating price fluctuations, delaying the adoption of advanced systems, and increasing the financial burden on hospitals and diagnostic centers.

At the same time, tariffs may encourage domestic manufacturing and investment in U.S.-based production facilities for PET systems and radiopharmaceuticals, potentially reducing long-term reliance on imports. However, given the highly specialized nature of PET technology, short-term disruptions are more likely to hinder adoption than stimulate immediate local production. For market players, this underscores the importance of strategic planning, including diversifying supply chains, negotiating tariff adjustments, and exploring local assembly options to mitigate risks.

How This Analysis Helps Clients

  • Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
  • Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
  • Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
  • Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the Positron Emission Tomography report study

  • Market size analysis for the current positron emission tomography size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the positron emission tomography.
  • Various opportunities available for the other competitors in the positron emission tomography space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current positron emission tomography scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for the positron emission tomography growth in the future?

Frequently Asked Questions for the Positron Emission Tomography

1. What is the growth rate of the positron emission tomography market?

  • The positron emission tomography is estimated to grow at a CAGR of 6.23% during the forecast period from 2025 to 2032.

2. What is the market for positron emission tomography?

  • The positron emission tomography was valued at USD 1,933.85 million in 2024, and is expected to reach USD 3,127.40 million by 2032.

3. Which region has the highest share in positron emission tomography?

  • North America is projected to hold the largest share of the global positron emission tomography market in 2024, driven by the rising prevalence of chronic diseases such as cancer and neurodegenerative disorders like Parkinson's disease. The region's growth is further supported by its advanced healthcare infrastructure, favorable reimbursement framework, and strong presence of leading imaging technology providers. The U.S. remains the frontrunner, with rapid adoption of innovative PET systems and substantial investments in R&D reinforcing its leadership position.

4. What are the drivers for positron emission tomography?

  • The growth of the global PET market is primarily driven by the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions, which is creating a strong demand for accurate and early diagnostic solutions. Alongside this, continuous technological advancements, including hybrid imaging systems, novel radiotracers, and total-body PET scanners, are significantly enhancing diagnostic precision and broadening clinical applications. Furthermore, the integration of PET with other imaging modalities such as CT and MRI is improving diagnostic confidence, treatment planning, and overall patient management. Collectively, these factors are positioning PET as a vital tool in modern healthcare, supporting its robust market growth during the forecast period from 2025 to 2032.

5. Who are the key players operating in positron emission tomography?

  • Some of the key market players operating in the positron emission tomography include General Electric Company, Bruker Corporation, Siemens Healthcare GmbH, Koninklijke Philips N.V., Canon Medical Systems Corporation, Positron Corporation, Shimadzu Corp., RefleXion, CMR Naviscan Corporation, Segami Corporation, Neusoft Medical Systems Co., Ltd., Mediso Ltd., Sofie Biosciences (PerkinElmer Inc.), United Imaging Healthcare Co., Ltd., MinFound Medical Systems Co., Ltd, MR Solutions, and others.

Table of Contents

1. Positron Emission Tomography Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Positron Emission Tomography Market Executive Summary

  • 2.1. Market at Glance

3. Positron Emission Tomography Market Key Factors Analysis

  • 3.1. Positron Emission Tomography Market Drivers
    • 3.1.1. Rising prevalence of chronic diseases
    • 3.1.2. Technological Advancements in Positron Emission Tomography Modalities
    • 3.1.3. Integration with other imaging modalities
  • 3.2. Positron Emission Tomography Market Restraints and Challenges
    • 3.2.1. Availability of alternative options
    • 3.2.2. Stringent regulatory approval
  • 3.3. Positron Emission Tomography Market Opportunity
    • 3.3.1. Development of novel radiotracers can enhance the specificity and sensitivity of PET scans

4. Impact Analysis

  • 4.1. AI-Powered Innovations and Applications
  • 4.2. U.S. Tariff Impact Analysis

5. Regulatory Analysis

  • 5.1. The United States
  • 5.2. Europe
  • 5.3. Japan
  • 5.4. China

6. Positron Emission Tomography Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Positron Emission Tomography Market Assessment

  • 7.1. By Type
    • 7.1.1. Full-Ring PET Scanners
    • 7.1.2. Partial Ring PET Scanners
  • 7.2. By Application
    • 7.2.1. Oncology
    • 7.2.2. Cardiology
    • 7.2.3. Cardiology
    • 7.2.4. Others
  • 7.3. By End-Users
    • 7.3.1. Hospitals
    • 7.3.2. Diagnostic Imaging Centres
    • 7.3.3. Others
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States Positron Emission Tomography Market Size in USD million (2022-2032)
      • 7.4.1.2. Canada Positron Emission Tomography Market Size in USD million (2022-2032)
      • 7.4.1.3. Mexico Positron Emission Tomography Market Size in USD million (2022-2032)
    • 7.4.2. Europe
      • 7.4.2.1. France Positron Emission Tomography Market Size in USD million (2022-2032)
      • 7.4.2.2. Germany Positron Emission Tomography Market Size in USD million (2022-2032)
      • 7.4.2.3. United Kingdom Positron Emission Tomography Market Size in USD million (2022-2032)
      • 7.4.2.4. Italy Positron Emission Tomography Market Size in USD million (2022-2032)
      • 7.4.2.5. Spain Positron Emission Tomography Market Size in USD million (2022-2032)
      • 7.4.2.6. Rest of Europe Positron Emission Tomography Market Size in USD million (2022-2032)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China Positron Emission Tomography Market Size in USD million (2022-2032)
      • 7.4.3.2. Japan Positron Emission Tomography Market Size in USD million (2022-2032)
      • 7.4.3.3. India Positron Emission Tomography Market Size in USD million (2022-2032)
      • 7.4.3.4. Australia Positron Emission Tomography Market Size in USD million (2022-2032)
      • 7.4.3.5. South Korea Positron Emission Tomography Market Size in USD million (2022-2032)
      • 7.4.3.6. Rest of Asia-Pacific Positron Emission Tomography Market Size in USD million (2022-2032)
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. Middle East Positron Emission Tomography Market Size in USD million (2022-2032)
      • 7.4.4.2. Africa Positron Emission Tomography Market Size in USD million (2022-2032)
      • 7.4.4.3. South America Positron Emission Tomography Market Size In USD Million (2022-2032)

8. Competitive Landscape

9. Startup Funding & Investment Trends

10. Positron Emission Tomography Market Company and Product Profiles

  • 10.1. General Electric Company
    • 1.1.1. Company Overview
    • 1.1.2. Company Snapshot
    • 1.1.3. Financial Overview
    • 1.1.4. Product Listing
    • 1.1.5. Entropy
  • 10.2. Bruker Corporation
    • 1.1.6. Company Overview
    • 1.1.7. Company Snapshot
    • 1.1.8. Financial Overview
    • 1.1.9. Product Listing
    • 1.1.10. Entropy
  • 10.3. Siemens Healthcare GmbH.
    • 1.1.11. Company Overview
    • 1.1.12. Company Snapshot
    • 1.1.13. Financial Overview
    • 1.1.14. Product Listing
    • 1.1.15. Entropy
  • 10.4. Koninklijke Philips N.V.
    • 1.1.16. Company Overview
    • 1.1.17. Company Snapshot
    • 1.1.18. Financial Overview
    • 1.1.19. Product Listing
    • 1.1.20. Entropy
  • 10.5. Canon Medical Systems Corporation
    • 1.1.21. Company Overview
    • 1.1.22. Company Snapshot
    • 1.1.23. Financial Overview
    • 1.1.24. Product Listing
    • 1.1.25. Entropy
  • 10.6. Positron Corporation
    • 1.1.26. Company Overview
    • 1.1.27. Company Snapshot
    • 1.1.28. Financial Overview
    • 1.1.29. Product Listing
    • 1.1.30. Entropy
  • 10.7. Shimadzu Corp.
    • 1.1.31. Company Overview
    • 1.1.32. Company Snapshot
    • 1.1.33. Financial Overview
    • 1.1.34. Product Listing
    • 1.1.35. Entropy
  • 10.8. RefleXion
    • 1.1.36. Company Overview
    • 1.1.37. Company Snapshot
    • 1.1.38. Financial Overview
    • 1.1.39. Product Listing
    • 1.1.40. Entropy
  • 10.9. CMR Naviscan Corporation
    • 1.1.41. Company Overview
    • 1.1.42. Company Snapshot
    • 1.1.43. Financial Overview
    • 1.1.44. Product Listing
    • 1.1.45. Entropy
  • 10.10. Segami Corporation
    • 1.1.46. Company Overview
    • 1.1.47. Company Snapshot
    • 1.1.48. Financial Overview
    • 1.1.49. Product Listing
    • 1.1.50. Entropy
  • 10.11. Neusoft Medical Systems Co., Ltd.
    • 1.1.51. Compan Overview
    • 1.1.52. Company Snapshot
    • 1.1.53. Financial Overview
    • 1.1.54. Product Listing
    • 1.1.55. Entropy
  • 10.12. Mediso Ltd.
    • 1.1.56. Company Overview
    • 1.1.57. Company Snapshot
    • 1.1.58. Financial Overview
    • 1.1.59. Product Listing
    • 1.1.60. Entropy
  • 10.13. Sofie Biosciences (PerkinElmer Inc.)
    • 1.1.61. Company Overview
    • 1.1.62. Company Snapshot
    • 1.1.63. Financial Overview
    • 1.1.64. Product Listing
    • 1.1.65. Entropy
  • 10.14. United Imaging Healthcare Co., Ltd.
    • 1.1.66. Company Overview
    • 1.1.67. Company Snapshot
    • 1.1.68. Financial Overview
    • 1.1.69. Product Listing
    • 1.1.70. Entropy
  • 10.15. MinFound Medical Systems Co., Ltd.
    • 1.1.71. Company Overview
    • 1.1.72. Company Snapshot
    • 1.1.73. Financial Overview
    • 1.1.74. Product Listing
    • 1.1.75. Entropy
  • 10.16. MR Solutions
    • 1.1.76. Company Overview
    • 1.1.77. Company Snapshot
    • 1.1.78. Financial Overview
    • 1.1.79. Product Listing
    • 1.1.80. Entropy

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer & Contact Us

List of Tables

  • Table 1: Positron Emission Tomography Market in Global (2022-2032)
  • Table 2: Positron Emission Tomography Market in Global by Type (2022-2032)
  • Table 3: Positron Emission Tomography Market in Global by Application (2022-2032)
  • Table 4: Positron Emission Tomography Market in Global by End-User (2022-2032)
  • Table 5: Positron Emission Tomography Market in Global by Geography (2022-2032)
  • Table 6: Positron Emission Tomography Market in North America (2022-2032)
  • Table 7: Positron Emission Tomography Market in the United States (2022-2032)
  • Table 8: Positron Emission Tomography Market in Canada (2022-2032)
  • Table 9: Positron Emission Tomography Market in Mexico (2022-2032)
  • Table 10: Positron Emission Tomography Market in Europe (2022-2032)
  • Table 11: Positron Emission Tomography Market in France (2022-2032)
  • Table 12: Positron Emission Tomography Market in Germany (2022-2032)
  • Table 13: Positron Emission Tomography Market in United Kingdom (2022-2032)
  • Table 14: Positron Emission Tomography Market in Italy (2022-2032)
  • Table 15: Positron Emission Tomography Market in Spain (2022-2032)
  • Table 16: Positron Emission Tomography Market in the Rest of Europe (2022-2032)
  • Table 17: Positron Emission Tomography Market in Asia-Pacific (2022-2032)
  • Table 18: Positron Emission Tomography Market in China (2022-2032)
  • Table 19: Positron Emission Tomography Market in Japan (2022-2032)
  • Table 20: Positron Emission Tomography Market in India (2022-2032)
  • Table 21: Positron Emission Tomography Market in Australia (2022-2032)
  • Table 22: Positron Emission Tomography Market in South Korea (2022-2032)
  • Table 23: Positron Emission Tomography Market in Rest of Asia-Pacific (2022-2032)
  • Table 24: Positron Emission Tomography Market in the Rest of the World (2022-2032)
  • Table 25: Positron Emission Tomography Market in the Middle East (2022-2032)
  • Table 26: Positron Emission Tomography Market in Africa (2022-2032)
  • Table 27: Positron Emission Tomography Market in South America (2022-2032)
  • Table 28: Competitive Landscape
  • Table 29: Startup Funding & Investment Trends

List of Figures

  • Figure 1: Positron Emission Tomography Market Drivers
  • Figure 2: Positron Emission Tomography Market Restraints
  • Figure 3: Positron Emission Tomography Market Opportunities
  • Figure 4: AI-Powered Innovations in Positron Emission Tomography Market
  • Figure 5: US Tariff Impact on Positron Emission Tomography Market
  • Figure 6: Regulatory Analysis (US, EU, Japan, China)
  • Figure 7: Porter's Five Forces Analysis
  • Figure 8: Competitive Analysis
  • Figure 9: Positron Emission Tomography Market in Global (2022-2032)
  • Figure 10: Positron Emission Tomography Market in Global by Type (2022-2032)
  • Figure 11: Positron Emission Tomography Market in Global by Application (2022-2032)
  • Figure 12: Positron Emission Tomography Market in Global by End-User (2022-2032)
  • Figure 13: Positron Emission Tomography Market in Global by Geography (2022-2032)
  • Figure 14: Positron Emission Tomography Market in North America (2022-2032)
  • Figure 15: Positron Emission Tomography Market in the United States (2022-2032)
  • Figure 16: Positron Emission Tomography Market in Canada (2022-2032)
  • Figure 17: Positron Emission Tomography Market in Mexico (2022-2032)
  • Figure 18: Positron Emission Tomography Market in Europe (2022-2032)
  • Figure 19: Positron Emission Tomography Market in France (2022-2032)
  • Figure 20: Positron Emission Tomography Market in Germany (2022-2032)
  • Figure 21: Positron Emission Tomography Market in United Kingdom (2022-2032)
  • Figure 22: Positron Emission Tomography Market in Italy (2022-2032)
  • Figure 23: Positron Emission Tomography Market in Spain (2022-2032)
  • Figure 24: Positron Emission Tomography Market in the Rest of Europe (2022-2032)
  • Figure 25: Positron Emission Tomography Market in Asia-Pacific (2022-2032)
  • Figure 26: Positron Emission Tomography Market in China (2022-2032)
  • Figure 27: Positron Emission Tomography Market in Japan (2022-2032)
  • Figure 28: Positron Emission Tomography Market in India (2022-2032)
  • Figure 29: Positron Emission Tomography Market in Australia (2022-2032)
  • Figure 30: Positron Emission Tomography Market in South Korea (2022-2032)
  • Figure 31: Positron Emission Tomography Market in Rest of Asia-Pacific (2022-2032)
  • Figure 32: Positron Emission Tomography Market in the Rest of the World (2022-2032)
  • Figure 33: Positron Emission Tomography Market in the Middle East (2022-2032)
  • Figure 34: Positron Emission Tomography Market in Africa (2022-2032)
  • Figure 35: Positron Emission Tomography Market in South America (2022-2032)
  • Figure 36: Competitive Landscape
  • Figure 37: Startup Funding & Investment Trends